Product Description
Mechanisms of Action: HCV-NS5A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil, Canada, India, Korea, Mauritius, Moldova, Pakistan, Philippines, Romania, South Africa, Turkey, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Hepatitis A|Hepatitis C, Chronic|Liver Cirrhosis
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2023-000160-54 | P2 |
Active, not recruiting |
Hepatitis C, Chronic |
2025-02-17 |
|
AT-01B-004 | P2 |
Active, not recruiting |
Liver Cirrhosis|Hepatitis A|Hepatitis C, Chronic |
2024-11-01 |
|
AT-01B-005 | P1 |
Completed |
Healthy Volunteers |
2024-08-25 |
|
AT-01B-006 | P1 |
Completed |
Healthy Volunteers |
2024-05-30 |